Articles By Wayne Koberstein, Executive Editor

Nancy Lurker - Eyepoint Pharma_450x300
Going Precommercial — From The Commercial World
Nancy Lurker, a veteran Big-Pharma marketer, now runs a small biopharma. And she admits, “the business models are very, very different.”  Continue Reading..
  • Companies To Watch: Atea Pharmaceuticals

    Atea Pharmaceuticals is creating new nucleotide antivirals, including one the company is jointly developing with Roche to fight COVID-19.

  • VCs Breathe New Life Into Life Sciences Industrials

    The “industrials” or supplier sector of the biopharma industry, in a significant change from the past, is now receiving an extra financial boost from VC funding. Why should their biopharma customers care?

  • Companies To Watch: AltruBio

    AltruBio’s new approach — regulating a checkpoint to mediate T cells in immune diseases — can surprise people more familiar with checkpoint-blocking cancer treatments now on the market.

  • Companies To Watch: AMO Pharma

    AMO Pharma is applying “de-risked” compounds as potential medicines for rare diseases in brain development.

  • Coming Out Of Stealth Mode: What To Know And Do

    In Part two of this two-part series, we look at what companies should do to make the exit from stealth mode an effective exchange with the outside world — how to identify and reach investors, influencers, and stakeholders in a company’s pursuit of new treatments for diseases, from rare conditions to widespread medical challenges, some at the scale of public health.

  • The Collective Benefits Of A Collaborative CFO

    Terry Coelho, CFO, works as a team member, not just a finance manager, at BioDelivery Sciences.

  • Companies To Watch: NervGen Pharma

    NervGen Pharma is going beyond preclinicals to human trials for a drug that could repair and regrow neurons.

  • Coming Out Of Stealth Mode: What To Know And Do

    Five CEOs discuss their experiences with stealth mode transitions. They address when and how a company should turn away from that introspective state and show itself to the world.

  • Companies To Watch: IM Therapeutics

    Our company to watch this month is IM Therapeutics, which focuses on developing small molecule therapies for Type 1 diabetes, celiac disease, and other autoimmune conditions.

  • Synergistic COVID Therapy Development

    From the outside, it may look as if Biophytis took a sharp turn from its focus on aging to address Covid. But look again.

  • Companies To Watch: Lyra Therapeutics

    Our company to watch this month, Lyra Therapeutics, is focused on controlling chronic ENT conditions with precise drug elution and long action.

  • 180 Life Sciences: Deliberately Seeking Serendipity

    At 180 Life Sciences, veterans of the old-pharma world are building a small bio enterprise focused evenly on scientific and market opportunities in the inflammation space.

  • Companies To Watch: Carisma Therapeutics

    Carisma Therapeutics is a private company developing CAR-M (chimeric antigen receptor macrophage) as an alternative to CAR-T (CAR-T cell) and potential treatment for solid tumors rather than just liquid cancers.

  • Canadian COVID Vax Comes Forward

    Long before the Warp Speed race, vaccines were a global business more characterized by collaboration than competition. In concert with its national regulator, Health Canada, IMV, Inc. could make world history with its approach to COVID vaccination.

wayne koberstein

Wayne Koberstein

Wayne Koberstein is a 30-year veteran of the publishing industry, with extensive experience in publishing, communications, and business development. Wayne has interviewed and profiled more than 300 top executives in pharmaceutical companies, as well as major regulatory and health care leaders, around the world. He has also created special media projects and conferences, in addition to serving widely as speaker, moderator, and advisor for industry meetings.